linjc16/ctgov huggingface dataset:
Multicenter Study on the Pathogenic Germline Gene Variants of Colorectal Polyposis in China

Study Overview
=================
Brief Summary
-----------------
Patients suspected of adenomatous polyposis were included. The criteria used were more than 10 polyps observed under colonoscopy, and pathological confirmation of adenoma. Clinical data and pedigree information were collected. The variants of 139 genes associated with different hereditary cancers and polyposis were screened by NGS, which was performed by Genetron Health on the HiSeqX-ten sequencing platform.

Official Title
-----------------
Multicenter Study on the Pathogenic Germline Gene Variants of Colorectal Polyposis in China

Conditions
-----------------
Colorectal Polyposis

Intervention / Treatment
-----------------
* Genetic: germline variants


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: clinical diagnosis of adenomatous polyposis; enough samples (provide at least 5ml of peripheral whole blood) for germline variant detection Exclusion Criteria: genetic diagnosis of polyposis syndrome
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| colorectal polyposis<br> | Genetic: germline variants<br>* Variants of 139 genes associated with different hereditary cancers and polyposis were screened by next-generation sequencing.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| germline variant detection rate in the polyposis population | germline variant detection rate in the polyposis population | through study completion, an average of 3 years |
Cervical Foraminal Stenosis and Radiculopathy - ACDF Versus Minimal Invasive Posterior Cervical Foraminotomy.

Study Overview
=================
Brief Summary
-----------------
A prospective randomized clinical trial. Cervical spondylotic foraminal stenosis with radiculopahty. Comparison results between 2 treatment options: ACDF and minimal invasive posterior cervical foraminiotomy. 80 patients to be followed for 2 years. Parameters to study: NDI, VAS, EQ-5D, complications, health economics, recurrens of stenosis, movement of facet joints pre- and postoperatively (foraminotomy group).

Official Title
-----------------
Cervical Foraminal Stenosis and Radiculopathy - Anterior Cervical Discectomy and Fusion (ACDF) Versus Minimal Invasive Posterior Cervical Foraminotomy miPCF).

Conditions
-----------------
Radiculopathy

Intervention / Treatment
-----------------
* Procedure: ACDF
* Procedure: minimal invasive Posterior Cervical Foraminotomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cervical radiculopathy on 1 or 2 levels correlated on MRI and CT Arm pain more than 30 (VAS). Duration more than 3 months. Exclusion Criteria: Myelopathy. Soft disc hernia. Previous neck surgery. Tumors, infection, WAD, trauma, generalized pain syndrome.

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: ACDF<br>Anterior Cervical Discectomy and Fusion | Procedure: ACDF<br> <br> |
| Active Comparator: miPCF<br>minimal invasive Posterior Cervical Foraminotomy | Procedure: minimal invasive Posterior Cervical Foraminotomy<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neck Disability Index |  | 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cervical foraminal stenosis minimal invasive foraminotomy
Resistance Training in Knee Osteoarthritis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether: Progressive resistance training improves pain and disability Progressive Resistance training improves muscular strength, ability to walk and quality of life

Detailed Description
-----------------
Patients in experimental group participated in a 12-week progressive resistance training using a repetition maximum (RM) exercise in which patients performed 1RM with the maximum bearable weight. Once the 1RM was determined, training was divided into the following regimen: 2 series of 8 repetitions, the first with 50% and the second with 70% of 1RM. The exercises were knee extension and flexion and hip abduction and adduction, all performed in machines. The 1RM load was reevaluated every 2 weeks. The control group remained on a three-month waiting list for physiotherapy. Patients were assessed for pain, function, quality of life, muscle strength and six-minute walk test.

Official Title
-----------------
Progressive Resistance Training in Women With Knee Osteoarthritis

Conditions
-----------------
Knee Osteoarthritis

Intervention / Treatment
-----------------
* Other: exercise


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Woman Age between 40-70 years old Pain between 3 and 8 on a 10-point numeric pain scale Radiographically confirmed knee OA Exclusion Criteria: Inflammatory diseases or any comorbidity that prohibit exercises, regular physical activity Trip plans for the next 12 months

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: exercise<br> | Other: exercise<br>* progressive resistance training<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain assessed on a 10-point numeric pain scale | Scale: visual analog scale | week 0 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Disability assessed on WOMAC | Western Ontario McMaster University Osteoarthritis Index Rheumatology An arthritic pain scoring system ranging from 0-no pain/disability to 100-most severe pain/disability WOMAC-pain, WOMAC-function and WOMAC-stifness | week 6 | 
| Quality of life assessed on the SF-36 | Questionnaire Short-form-36 | week 6 | 
| Six-minute walk test | To assess distance walked in 6 minutes | week 12 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Knee, Osteoarthritis, Exercise
Automated Screen for Fetal Aneuploidy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to develop and evaluate a blood test and automated microfluidic test platform for the prenatal screening of fetal aneuploidy.

Official Title
-----------------
Fluidic Automated Screening for Trisomy Study I

Conditions
-----------------
Trisomy 21 and Other Fetal Aneuploidy

Intervention / Treatment
-----------------
* Diagnostic Test: blood test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject is at least 18 years old and can provide informed consent; Subject has a viable singleton or twin pregnancy; Subject is confirmed to be at least 10 weeks, 0 days gestation at the time of the study blood draw; Subject is planning to undergo chorionic villus sampling and/or amniocentesis for the purpose of genetic analysis of the fetus because of a suspected fetal chromosomal anomaly based on cell-free DNA test results, standard serum screening result, or fetal ultrasound abnormality. OR the subject has already undergone chorionic villus sampling and/or amniocentesis and is known to have a fetus with a chromosomal abnormality confirmed by genetic analysis. Exclusion Criteria: Subject (the mother) has known aneuploidy; Subject is pregnant with more than two fetuses or has had sonographic evidence of three or more gestational sacs at any time during pregnancy; Subject has a fetal demise (including natural or elective reduction) identified prior to consent; Subject has history of malignancy treated with chemotherapy and/or major surgery, or bone marrow transplant.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| positive for fetal aneuploidy<br> | Diagnostic Test: blood test<br>* analysis of cell-free DNA in maternal plasma<br>|
| negative for fetal aneuploidy<br> | Diagnostic Test: blood test<br>* analysis of cell-free DNA in maternal plasma<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of blood test to fetal karyotype | Maternal plasma cell-free DNA will be analyzed to determine copy number of specific chromosomes and compared to the fetal karyotype as obtained through invasive diagnostic testing of the fetus. | 21 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
fetal, screening test, trisomy, aneuploidy, copy number variant
Self-Efficacy Enhancing Interviewing Techniques Study

Study Overview
=================
Brief Summary
-----------------
Patient self-efficacy, or confidence in one's ability to take the necessary steps to achieve a goal, has been shown to influence a number of important health behaviors and outcomes. However, current ways of increasing patient self-efficacy are time and labor intensive and occur away from doctor visits, where most health care is delivered. We developed, and are testing in a study the effectiveness of a new way of teaching doctors how to talk to patients during office visits in a way that will boost their patients' self-efficacy for changing important health behaviors.

Official Title
-----------------
Self-Efficacy Enhancing Interviewing Techniques Study

Conditions
-----------------
Diabetes, Depression, Anxiety, Asthma, Post-Traumatic Stress Disorder

Intervention / Treatment
-----------------
* Behavioral: Self-efficacy enhancing interviewing techniques training
* Behavioral: Control intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Family medicine or internal medicine residents in training at the University of California Davis Medical Center Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>These residents receive training provided by standardized patient instructors, in use of self-efficacy enhancing interviewing techniques to support patient health behavior change, | Behavioral: Self-efficacy enhancing interviewing techniques training<br>* Teaching by standardized patient instructors regarding use of self-efficacy enhancing interviewing techniques to be applied in patient encounters<br>|
| Active Comparator: 2<br>These residents receive training provided by a standardized patient instructor, regarding the common co-occurrence of chronic medical and mental health problems, without any interviewing technique discussion or training. | Behavioral: Control intervention<br>* These residents receive training provided by a standardized patient instructor, regarding the common co-occurrence of chronic medical and mental health problems, without any interviewing technique discussion or training.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Resident physician use of self-efficacy enhancing patient interviewing techniques, assessment via coding of audio recordings from standardized patient encounters |  | Within 6 months of completion of intervention | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
self-efficacy, chronic illness, health behavior, education, medical, residency
Musculoskeletal Outcomes After Bone Marrow Transplant

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to evaluate bone mineral density and muscle strength in survivors of bone marrow transplant. Association with age, type of transplant, steroids, years since transplant, body composition, endocrinopathies, radiation, quality of life and physical activity will be explored.

Detailed Description
-----------------
Bone marrow transplant survivors are at risk of diminished bone mineral density. Mechanisms and risks are not well understood. This study will help identify risks factors for developing this complication.

Official Title
-----------------
Musculoskeletal Outcomes After Bone Marrow Transplant

Conditions
-----------------
Survivors of Bone Marrow Transplant, Autologous and Allogeneic

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ages 8-30 years One year from transplant Exclusion Criteria: No current steroid use Medical conditions that would prohibit testing Neuropsychological conditions that prohibit completing questionnaires

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bone Marrow Transplant, Bone Mineral Density, Survivors, Muscle Strength
A Study of the Side Effects of L-743,872 in Men With Candidal Esophagitis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to see if it is safe to give L-743,872 to men with candidal esophagitis, an AIDS-related yeast infection in the esophagus.

Detailed Description
-----------------
In this open-label study, patients receive intravenous L-743,872 every 24 hours at one of three dose levels for 14 days. Post-study safety evaluations continue for 4 weeks after the final dose. Pharmacokinetics and safety measurements are taken throughout the 6-week study.

Official Title
-----------------
An Open, Serial-Panel, Multiple-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of L-743,872 in Patients With Candida Esophagitis

Conditions
-----------------
Candidiasis, Esophageal, HIV Infections

Intervention / Treatment
-----------------
* Drug: L-743,872


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria You may be eligible for this study if you: Are an 18- to 65-year-old man with candidal esophagitis.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: L-743,872|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dose-Response Relationship, Drug, Antifungal Agents, Candidiasis, Esophageal Diseases, MK 0991
Evaluate the Efficacy of a Global Dental Health Promotion Program on Dental Hygiene in Patients With Schizophrenia.

Study Overview
=================
Brief Summary
-----------------
There are few disease prevention programs or programs to manage somatic disorders in a psychiatric context. The aim of this study is to evaluate the impact in the medium term of a global program to promote dental health on buccodental hygiene in patients with schizophrenia and the ability of these patients to follow the intervention. This is an interventional trial, randomized in clusters. The participating establishments will be randomized to the intervention group (promotion program) or the control group (surveillance). For each patient, the study will last 12 months altogether and will include an initial evaluation of dental health, a 6-month education program for dental care (for patients in the intervention group) and a follow-up at 6 and 12 months after the start of the study. The follow-up will evaluate dental health and quality of life.

Official Title
-----------------
Efficacy of a Dental Health Promotion Program in Patients With Schizophrenia

Conditions
-----------------
Schizophrenia

Intervention / Treatment
-----------------
* Other: Dental care education program
* Other: Surveillance


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with a confirmed diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM V) Managed at a specialized establishment Older than 18 years. who have provided written informed consent to take part in the study Exclusion Criteria: Fully hospitalized patients Patients who are unstable from a psychiatric poit of view or who suffer from delirium. Subjects with less than one incisor, canine, premolar and molar on each hemi-arch Patients with a risk of infectious endocarditis or a major risk of superinfection Patients on long-term treatment with antibiotics (Impact of antibiotherapy on oral flora) Patients treated with chemotherapy Pregnant or breastfeeding women Patients without National Health Insurance cover. Poor written and/or oral comprehension of the French language

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intervention<br> | Other: Dental care education program<br>* Dental care education program<br>|
| Placebo Comparator: Surveillance<br> | Other: Surveillance<br>* Surveillance<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of patients with a Community Peridontal Index (CPI) ≥3 |  | 6 months |
Autoimmunity in Inner Ear Disease

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether prednisone, methotrexate, and cyclophosphamide are effective in the treatment of rapidly progressive sensorineural hearing loss in both ears. This condition is called autoimmune inner ear disease (AIED), because it is thought that the hearing loss is triggered by an autoimmune process. Treatment attempts to suppress or control this process with powerful anti-inflammatory drugs. This is a Phase III, outpatient study. All study participants will be assigned to one of four different groups testing the experimental use of drugs. The study is scheduled to run for 18 months, with a minimum of 11 visits per participant.

Conditions
-----------------
Hearing Loss, Sensorineural

Intervention / Treatment
-----------------
* Drug: Corticosteroids
* Drug: Methotrexate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Have sensorineural (nerve/inner ear) hearing loss of at least 30 dB in each ear, which has rapidly progressed. Are in good general health. Are sterile or use contraception (if a woman of child-bearing age). Are able to speak and understand English or Spanish. Exclusion Criteria: Have had any previous reaction to prednisone, or history of psychiatric reaction to corticosteroids. Have used corticosteroids for more than 30 days within the past 90 days. Patients who have been off corticosteroids for at least 30 days may be eligible. Have any significant heart, lung, digestive, blood, or neurologic disorders. Have tuberculosis (TB), brittle or unstable insulin-dependent diabetes mellitus, active malignancy or prior chemotherapy, pancreatitis, active peptic ulcer disease, kidney failure, history of shingles, or known (other) autoimmune disease. Have had a positive test for HIV, hepatitis C or B. Have any type of middle ear disorder. Are breast-feeding or pregnant.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Corticosteroids|nan|
|Drug: Methotrexate|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Autoimmune Diseases, Cyclophosphamide, Hearing, Labyrinth Diseases, Methotrexate, Prednisone